Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Murin

Showing results (231-240 of 315) with videos related to

Pageof 32
Sort By:
Molecules (Basel, Switzerland)|March 25, 2020
Chemopreventive and Therapeutic Efficacy of <i>Cinnamomum zeylanicum</i> L. Bark in Experimental Breast Carcinoma: Mechanistic In Vivo and In Vitro AnalysesPeter Kubatka, Martin Kello, Karol Kajo, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|July 28, 2023
C<sub>60</sub> adduct with L-arginine as a promising nanomaterial for treating cerebral ischemic strokeOlegi N Kukaliia, Sergei V Ageev, Andrey V Petrov, et al.
Journal of the American College of Cardiology|March 19, 2021
Long-Term Outcomes of Patients Undergoing the Ross ProcedureAnas Aboud, Efstratios I Charitos, Buntaro Fujita, et al.
Cell|October 29, 2021
Pan-ebolavirus protective therapy by two multifunctional human antibodiesPavlo Gilchuk, Charles D Murin, Robert W Cross, et al.
Plos Pathogens|June 27, 2015
Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPsMarnie L Fusco, Takao Hashiguchi, Robyn Cassan, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 20, 2019
The evolution and genomic basis of beetle diversityDuane D McKenna, Seunggwan Shin, Dirk Ahrens, et al.
Nature Microbiology|May 9, 2018
Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER regionAndrew I Flyak, Natalia Kuzmina, Charles D Murin, et al.
Cell|January 26, 2016
Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus InfectionAndrew I Flyak, Xiaoli Shen, Charles D Murin, et al.
Cell|May 20, 2017
Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against EbolavirusesAnna Z Wec, Andrew S Herbert, Charles D Murin, et al.
The Lancet. Diabetes & Endocrinology|July 6, 2019
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trialKausik K Ray, Helen M Colhoun, Michael Szarek, et al.
Pageof 32

Showing results (231-240 of 315) with videos related to

Sort By:
Pageof 32
Molecules (Basel, Switzerland)|March 25, 2020
Chemopreventive and Therapeutic Efficacy of <i>Cinnamomum zeylanicum</i> L. Bark in Experimental Breast Carcinoma: Mechanistic In Vivo and In Vitro AnalysesPeter Kubatka, Martin Kello, Karol Kajo, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|July 28, 2023
C<sub>60</sub> adduct with L-arginine as a promising nanomaterial for treating cerebral ischemic strokeOlegi N Kukaliia, Sergei V Ageev, Andrey V Petrov, et al.
Journal of the American College of Cardiology|March 19, 2021
Long-Term Outcomes of Patients Undergoing the Ross ProcedureAnas Aboud, Efstratios I Charitos, Buntaro Fujita, et al.
Cell|October 29, 2021
Pan-ebolavirus protective therapy by two multifunctional human antibodiesPavlo Gilchuk, Charles D Murin, Robert W Cross, et al.
Plos Pathogens|June 27, 2015
Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPsMarnie L Fusco, Takao Hashiguchi, Robyn Cassan, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 20, 2019
The evolution and genomic basis of beetle diversityDuane D McKenna, Seunggwan Shin, Dirk Ahrens, et al.
Nature Microbiology|May 9, 2018
Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER regionAndrew I Flyak, Natalia Kuzmina, Charles D Murin, et al.
Cell|January 26, 2016
Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus InfectionAndrew I Flyak, Xiaoli Shen, Charles D Murin, et al.
Cell|May 20, 2017
Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against EbolavirusesAnna Z Wec, Andrew S Herbert, Charles D Murin, et al.
The Lancet. Diabetes & Endocrinology|July 6, 2019
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trialKausik K Ray, Helen M Colhoun, Michael Szarek, et al.
Pageof 32